Retinal Vein and Artery Occlusion

Retinal vascular occlusions rank among the most common causes of sudden, painless vision loss in adults over 50 — second only to diabetic retinopathy as a cause of retinal vascular disease (NEI). When blood flow through the eye's intricate vascular network is interrupted, the consequences can range from a mild, temporary blur to permanent central vision loss — sometimes within hours of onset.

What the Retinal Vasculature Does

The retina, a tissue roughly the thickness of a piece of paper, demands a disproportionate share of the body's oxygen supply. It is served by two separate vascular systems: the central retinal artery (CRA), which branches off the ophthalmic artery and supplies the inner retinal layers, and the choroidal circulation beneath it. Both systems converge at a single anatomical chokepoint — the optic nerve head — where blockages carry outsized consequences.

Types of Occlusion

Central Retinal Vein Occlusion (CRVO)

CRVO occurs when the central retinal vein is blocked, typically at or posterior to the lamina cribrosa. Blood backs up across the entire retina, producing the classic "blood-and-thunder" fundus: flame-shaped hemorrhages in all 4 quadrants, dilated tortuous veins, disc edema, and cotton-wool spots. The condition is classified as either ischemic or non-ischemic; ischemic CRVO, present in roughly 25% of cases, carries a significantly worse visual prognosis (American Academy of Ophthalmology).

Branch Retinal Vein Occlusion (BRVO)

BRVO is the more common of the two vein occlusion subtypes. It typically occurs at an arteriovenous crossing, where a thickened artery compresses the adjacent vein. The superior temporal quadrant is involved in approximately 63% of BRVO cases (American Academy of Ophthalmology). Vision loss is often less severe than CRVO, though macular edema can produce significant central distortion.

Central Retinal Artery Occlusion (CRAO)

CRAO is a true ocular emergency — functionally, it is a stroke of the eye. The retina tolerates ischemia poorly; irreversible photoreceptor damage begins within 90 to 100 minutes of onset (MedlinePlus / National Library of Medicine). The classic fundus presentation is a pale, opacified retina with a cherry-red spot at the fovea, where the underlying choroidal circulation remains visible through the thin foveal tissue. Emboli — cholesterol (Hollenhorst plaques), calcific, or thrombotic — are identified in approximately 20–40% of CRAO cases.

Branch Retinal Artery Occlusion (BRAO)

BRAO produces a wedge-shaped area of retinal whitening corresponding to the territory of the occluded branch. Patients often report an arcuate visual field defect rather than total vision loss. Because the macula may be spared, some BRAO presentations are subtle enough to be dismissed initially.

Risk Factors and Systemic Associations

Retinal vein occlusions are strongly associated with hypertension, which is present in 64–73% of affected patients, and with open-angle glaucoma, elevated intraocular pressure, and hyperlipidemia (National Eye Institute). Thrombophilic conditions — including antiphospholipid syndrome, Factor V Leiden mutation, and hyperhomocysteinemia — are identified in a subset of younger patients without conventional cardiovascular risk factors.

Retinal artery occlusions carry an even more urgent systemic signal. A CRAO is associated with a 90-day stroke risk of approximately 10%, according to data published by the American Stroke Association — a figure that drives the current recommendation to evaluate these patients with the same urgency as transient ischemic attacks.

Diagnosis

Fundus examination remains the cornerstone of diagnosis. Optical coherence tomography (OCT) quantifies macular edema with submicron precision and guides treatment decisions. Fluorescein angiography (FA) characterizes ischemia extent and is indispensable in distinguishing ischemic from non-ischemic CRVO. OCT angiography (OCTA), a non-invasive modality, can map the superficial and deep capillary plexuses without dye injection — increasingly useful for monitoring perfusion over time.

Treatment

Retinal Vein Occlusions

The therapeutic landscape shifted decisively with the introduction of intravitreal anti-VEGF agents. Ranibizumab (Lucentis) received FDA approval for macular edema following RVO in 2010; aflibercept (Eylea) followed in 2012. Both demonstrated statistically significant visual acuity gains over sham injection in the landmark BRAVO, CRUISE, and COPERNICUS trials (ClinicalTrials.gov). Intravitreal corticosteroids — including the dexamethasone implant (Ozurdex) — offer an alternative, particularly for patients who are poor candidates for frequent injections, though cataract progression and intraocular pressure elevation are established risks.

Grid laser photocoagulation retains a role in BRVO-related macular edema that is non-responsive to pharmacotherapy.

Retinal Artery Occlusions

CRAO management remains genuinely unsettled — a humbling gap in a field with otherwise robust treatment algorithms. Ocular massage, anterior chamber paracentesis, and hyperbaric oxygen have all been employed without high-quality evidence supporting any single intervention. The EAGLE trial, published in JAMA Neurology in 2021, evaluated intra-arterial thrombolysis for CRAO and found no significant benefit over standard care alone, tempering earlier enthusiasm for aggressive intervention. The dominant recommendation is emergency vascular and neurological evaluation to mitigate stroke risk.

Prognosis

Visual outcomes vary considerably by occlusion type, duration of ischemia, and macular involvement. Non-ischemic CRVO patients have approximately a 30–50% chance of spontaneous visual improvement; ischemic CRVO patients rarely recover meaningful central vision without aggressive treatment. CRAO carries the grimest prognosis of the group — final visual acuity of 20/400 or worse is documented in more than 50% of untreated patients (MedlinePlus/NLM).

Regular systemic follow-up is not optional in these patients. Retinal vascular occlusion is frequently the first sign that the cardiovascular system has been accumulating damage quietly for years.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)